Neoplasms, Breast Clinical Trial
Official title:
A Phase II Study to Evaluate the Efficacy, Safety, and Pharmacodynamics of Lapatinib in Combination With Paclitaxel as Neoadjuvant Therapy in Patients With Newly Diagnosed Inflammatory Breast Cancer
This Study was designed to determine how effective and safe a new investigational drug, lapatinib, is in combination with paclitaxel in treating patients with newly diagnosed inflammatory breast cancer. Tumor tissue collected pre-treatment, following 14 days of treatment and at the time of surgical resection will be examined for pathologic response and biologic activity by IHC (immunohistochemistry) within the tumor. Treatment will consist of 14 days of lapatinib monotherapy followed by 12 weeks of combination therapy with lapatinib and paclitaxel. Blood samples for hematology and chemistry panels, MUGA/ECHO exams and physical exams will be performed throughout the study to monitor safety.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Terminated |
NCT00251433 -
GW572016 With Docetaxel and Trastuzumab for the Treatment Of Untreated ErbB2 Over-Expressing Metastatic Breast Cancer
|
Phase 1 | |
| Completed |
NCT01271738 -
Evaluating and Comparing Two Surgical Methods for Treatment of Early Stage Breast Cancer
|
N/A | |
| Recruiting |
NCT04892342 -
Study of ESG401 in Adults With Solid Tumors
|
Phase 1/Phase 2 | |
| Terminated |
NCT02213042 -
Evaluation of Biomarkers Associated With Response to Subsequent Therapies in Subjects With HER2-Positive Metastatic Breast Cancer
|
Phase 2 | |
| Withdrawn |
NCT01137994 -
A Phase II, Randomized, Open-label Study of Lapatinib Plus Chemotherapy Versus Trastuzumab Plus Chemotherapy in HER2-positive and p95HER2-positive Metastatic Breast Cancer
|
Phase 2 | |
| Completed |
NCT00790816 -
Continuation Study of Lapatinib Monotherapy or Lapatinib in Combination With Other Anti-cancer Agents
|
Phase 1 | |
| Completed |
NCT00051103 -
Oral Drug Study In Women With Refractory Metastatic Breast Cancer After First-line or Second-line Herceptin.
|
Phase 2 | |
| Completed |
NCT00320411 -
GW572016 In Patients With ErbB2 Over - Expressing Advanced Or Metastatic Breast Cancer
|
Phase 2 | |
| Completed |
NCT00258050 -
To Examine The Effects Of Lapatinib On Orally And Intravenously Administered Midazolam In Cancer Patients
|
Phase 1 | |
| Terminated |
NCT01498588 -
Trial of Eribulin Followed by Doxorubicin & Cyclophosphamide for Her2-negative, Locally Advanced Breast Cancer
|
Phase 2 | |
| Terminated |
NCT00479856 -
Lapatinib In Combination With Chemotherapy In Subjects With Relapsed Breast Cancer
|
Phase 2 | |
| Completed |
NCT00320385 -
Lapatinib In Combination With Trastuzumab Versus Lapatinib Monotherapy In Subjects With HER2-positive Metastatic Breast Cancer
|
Phase 3 | |
| Completed |
NCT00062686 -
GW572016 For Treatment Of Refractory Metastatic Breast Cancer
|
Phase 2 | |
| Completed |
NCT00996762 -
A Study in Cancer Patients to Evaluate the Bioequivalence of Alternative Formulations of Lapatinib
|
Phase 1 | |
| Terminated |
NCT02913729 -
Pre- Versus Postoperative Accelerated Partial Breast Irradiation
|
N/A | |
| Completed |
NCT01160211 -
A Study to Compare the Safety and Efficacy of an Aromatase Inhibitor in Combination With Lapatinib, Trastuzumab or Both for the Treatment of Hormone Receptor Positive, HER2+ Metastatic Breast Cancer
|
Phase 3 | |
| Recruiting |
NCT05814224 -
Monitoring luminAl Breast Cancer Through the Evaluation of Mutational and epiGeNEtic alteraTIons of Circulating ESR1 DNA
|
N/A | |
| Completed |
NCT01815294 -
A Pivotal Bioequivalence Study of DOXIL/CAELYX (Doxorubicin HCL) in Patients With Advanced or Refractory Solid Malignancies Including Patients With Ovarian Cancer
|
Phase 1 | |
| Terminated |
NCT00437073 -
Brain Metastases In ErbB2-Positive Breast Cancer
|
Phase 2 | |
| Completed |
NCT00356811 -
Lapatinib Combined With Paclitaxel For Patients With First-Line ErbB2-Amplified Metastatic Breast Cancer
|
Phase 2 |